Alzheimer’s disease (AD) is the leading cause of dementia, characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. Genetic predispositions, aging, systemic inflammation, and lifestyle factors contribute to its development. The disease progresses over 15-20 years, from initial amyloid pathology to overt dementia. Early intervention is crucial, and biomarkers in blood are essential for early diagnosis and personalized treatment. Recent advances in biomarker research and the FDA approval of anti-Aβ monoclonal antibodies offer hope for better management and treatment.
Key Insights from the review include:
This review highlights the multifaceted nature of Alzheimer’s disease, emphasizing the importance of genetic predispositions, modifiable risk factors, and the progressive pathophysiology of the disease. Early intervention and the use of biomarkers for diagnosis and personalized treatment are crucial for improving patient outcomes. While recent advances in therapeutic strategies show promise, more targeted and effective interventions are needed to reduce the burden of AD. The work entitled “ Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy ” was published on Protein & Cell (published on May. 11, 2024).
Protein & Cell
Systematic review
Not applicable
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
11-May-2024